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ABSTRACT
The mounting evidence supporting the capacity of Plasmodium vivax to cause severe disease has 
prompted the need for a better characterization of the resulting clinical complications. India is 
making progress with reducing malaria, but epidemics of severe vivax malaria in Gujarat, one of 
the main contributors to the vivax malaria burden in the country, have been reported recently 
and may be the result of a decrease in transmission and immune development. Over a period of 
one year, we enrolled severe malaria patients admitted at the Civil Hospital in Ahmedabad, the 
largest city in Gujarat, to investigate the morbidity of severe vivax malaria compared to severe 
falciparum malaria. Patients were submitted to standard thorough clinical and laboratory inves-
tigations and only PCR-confirmed infections were selected for the present study. Severevivax 
malaria (30 patients) was more frequent than severe falciparum malaria (8 patients) in our setting, 
and it predominantly affected adults (median age 32 years, interquartile range 22.5 years). This 
suggests a potential age shift in anti-malarial immunity, likely to result from the recent decrease in 
transmission across India. The clinical presentation of severe vivax patients was in line with 
previous reports, with jaundice as the most common complication. Our findings further support 
the need for epidemiological studies combining clinical characterization of severe vivax malaria 
and serological evaluation of exposure markers to monitor the impact of elimination programmes.
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Introduction
Plasmodium vivax(Pv) is the most geographically prevalent 
human malaria parasite, with 2.5 billion individuals at risk 
of infection worldwide [1]. Historically, Pv infection has 
been perceived as relatively benign, despite being debilitat-
ing and often life-threatening. As a result, clinical malaria 
research has mainly focused on Plasmodium falciparum 
(Pf) morbidity and mortality to date [2,3]. However, 
Pvhas now become the predominant cause of malaria out-
side sub-Saharan Africa and is considered a key obstacle to 
malaria elimination [4]. This is particularly relevant in 
India, which remains the largest contributor to Pv burden 
globally [5,6], and where there has been an increase in 
reports supporting the capacity of Pv to induce severe 
and potentially fatal malaria in recent years [7–11]. This 
may be attributed to a combination of several factors, 
including historical underreporting, improved diagnostic 
granularity, and the availability of molecular tools to accu-
rately differentiate parasite species and potential co- 
infections, or drug resistance emergence [10].
Gujarat is one of the major states contributing to the Pv 
burden in India, with a Pv/Pf ratio around 80:20 [12]. 
Remarkably, about one in five malaria-associated deaths 
reported in that state has been attributed to Pv [12,13]. 
This is in line with the mounting evidence for the ability 
of Pvto induce a wide spectrum of severe malaria, with 
a risk of death similar to that observed for Pf infection 
[3,7,8,10,11]. Pv invades primarily reticulocytes and uses 
the Duffy antigens expressed on the red blood cells as 
a receptor [3,14,15]. It is often found circulating at low 
parasite densities in the peripheral blood and has the 
ability to produce hypnozoites, or dormant liver stages, 
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which lead to recurrent infections [3]. Several reports 
have shown the presence of Pv stages in the spleen, 
lungs, and bone marrow [16–20], suggesting that contrary 
to another common belief, Pv-infected reticulocytes may 
sequester and therefore play a role in the development of 
severe Pvmalaria.
Endemic areas differ widely in terms of transmission, 
population immunity, and resulting severe disease fre-
quency, prompting the need for a more comprehensive 
characterization of the spectrum of clinical complications 
in India. We conducted a prospective study to follow 
severe malaria patients with PCR-confirmed diagnosis 
admitted to the Ahmedabad Civil hospital in Gujarat, 
India, over a one-year period (December 2016 – 
November 2017), with the aim to meticulously differenti-
ate and compare clinical and laboratory characteristics-
betweensevere PvandPfmalaria infections.
Materials and methods
Study site
The study was set up in the state of Gujarat, which has 
the third highest Pv malaria burden in the country, 
accounting for 9% of the national total [12]. Patients 
were enrolled at the Civil Hospital in Ahmedabad, the 
largest city in Gujarat with an extended population of 
6.3 million. Affiliated with the ByramjeeJeejeebhoy 
Medical College, the hospital is the largest in Gujarat, 
with 4,800 inpatient beds, and over 100,000 admissions 
per year. It is the main referral hospital for the 
adjoining districts of Mehsana, Gandhinagar, Kheda, 
Anand, Botad, Bhavnagar, and Surendranagar, and 
has facilities for dialysis and ventilation. Anopheles 
culicifacies, An. stephensi, and An. fluviatilis are the 
major malaria vectors in the region, with transmission 
closely following the monsoon, from mid-June to mid- 
October [12].
Study design and patient selection
This prospective, hospital-based study focused on patients 
admitted with severePf, Pvor Pf/Pv co-infections, and was 
conducted between December 2016 and November 2017. 
Microscopy-diagnosed Pf and Pv infections with or with-
out WHO-defined severe malaria symptoms [21,22] 
(Table 1), as well as one case of suspected malaria but 
with negative microscopy results, were enrolled after 
informed consent forms were obtained from patients or 
their legal representatives. 200μlof packed red blood cells 
was collected and used for PCR confirmation of 
Plasmodium species (Pf, Pv, P. malariae, P. ovale), and 
only PCR-confirmed cases were selected for the subse-
quent analyses.
Clinical assessment and treatment
The clinical team performed a physical examination at 
the time of admission, and patients with suspected 
malaria infection were tested for Pf and Pv by micro-
scopy and subsequently by PCR. Blood count, bio-
chemistry analyses, chest X-rays, blood culture, and 
Table 1. Criteria used for the definition of severe malaria.
Clinical features Description
Impaired consciousness Including unarousable coma 
Assessment by Glasgow scale (10 or less) or Blantyre scale (3 or less) 
Normal cerebrospinal fluid
Prostration Generalized weakness so that the patient is unable to sit, stand, or walk without assistance
Multiple convulsions Jerky limb movements and staring eyes; more than two episodes within 24 hours
Deep breathing and respiratory distress Acidotic breathing, arterial pH <7.35
Acute pulmonary oedema and acute respiratory distress 
syndrome
Tachypnea, dyspnea, and bilateral basal rales
Circulatory collapse or shock Systolic blood pressure <80 mm Hg in adults, and <50 mm Hg in children
Acute kidney injury Urine output <400 ml/24 hours in adults and <0.5 ml/kg in children
Clinical jaundice plus evidence of other vital organ 
dysfunction
Serum bilirubin > 3 mg/dl
Abnormal bleeding Spontaneous bleeding at gums, nose, venipuncture sites, gastrointestinal tract, blood tests 
suggestive of disseminated intravascular coagulation
Laboratory
Hypoglycemia <2.2 mmol/l or < 40 mg/dl. 
Anxiety, sweating, palpitation, dilatation of pupils, breathlessness, convulsions, alteration 
of consciousness
Metabolic acidosis Plasma bicarbonate < 15 mmol/l
Severe normocytic anemia Hemoglobin,5 g/dl or packed cell volume < 15% in children, hemoglobin <7 g/dl or packed 
cell volume <20% in adults
Hemoglobinuria Urine is positive for hemoglobin
Hyperlactatemia* Lactate > 5 mmol/l
Renal impairment Blood urea > 20 mM
Pulmonary oedema Radiological: bilateral infiltration in the lungs on chest film
Hyperparasitemia Parasite density > 100,000/µl (~ 2.5% parasitemia), appearance of peripheral schizontemia
*Not measured in our cohort. 
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serology tests were also performed if deemed necessary 
by the physician in charge. Pv- or Pf-positive patients 
were then approached for enrolment and an additional 
5 ml of blood was collected from enrolled individuals to 
evaluate potential co-infections. Clinical data were 
compiled in a case report form, which also included 
a history of previous malaria infections and the use of 
antimalarials, as well as pregnancy status for women of 
reproductive age. Treatments for Pf, Pv [23] and other 
co-infections (such as typhoid, dengue, chikungunya, 
tuberculosis, and viral hepatitis infections) were pro-
vided according to national guidelines of India. Clinical 
assessments and routine microscopy were performed 
on a daily basis until the patient recovered/died. 
Additional and follow-up laboratory tests were per-
formed at the physician’s discretion, including serology 
tests and blood culture.
Malaria diagnosis
Thick and thin microscopy blood smears were air-dried, 
stained with Giemsa, and examined using a light micro-
scope. Blood samples were subjected to DNA extraction 
using the Qiagen® QIAamp DNA Midi Kits followed by 
PCR amplification to assess the presence of Plasmodium 
species based on the protocol described elsewhere [24–26]. 
Briefly, 25 μl of PCR reactions were prepared including 5 μl 
of template DNA, primers, and 1x master mix (GoTaq 
Green, Promega), reaction volume was raised by PCR- 
grade water. A BioRad T100 thermal cycler was used for 
amplification, and PCR products were run on 1.5% agarose 
gels (Agarose LE, Promega) in 1× TBE buffer (Thermo 
Scientific) to determine the presence of the amplified 
DNA, and PCR products were visualized using a UV trans- 
illuminator (BioRad Gel Doc EZ System). Different 
Plasmodium species were identified based on the amplified 
product sizes, as previously described [24–26].
Ethical statement
Institutional Review Board approval was obtained from 
New York University and Institutional Ethical 
Clearance from NIMR. Informed consent was obtained 
from all subjects or, if subjects were under 18, from 
a parent and/or legal guardian. All laboratory tests were 
performed in accordance with the relevant guidelines 
and regulations.
Dataset generation and statistical analysis
All case record forms (CRFs) were anonymized, digitized, 
and stored using the REDCap (Research Electronic Data 
Capture) system, which allowed subsequent extraction of 
datasets [27]. Chi-squared and Mann–Whitney U tests 
were used to compare categorical and continuous variables, 
respectively. Odds ratio (OR), 95% confidence interval 
(95% CI), and p-value were calculated using an online 
version of MedCalc software (https://www.medcalc.org/ 
calc/odds_ratio.php). A two-sided p < 0.05 was considered 
statistically significant. All statistical analyses were per-
formed using GraphPad Prism 8.0 (GraphPad Software).
Data deposition
The study data are available for download through the 
Clinical Epidemiology Database (ClinEpiDB) [28] at 
https://clinepidb.org.
Results
Patients
Forty-one out of 50 enrolled patients were Plasmodium 
positive and diagnosed using PCR amplifications either 
for Pf, Pv, or Pf/Pv co-infection. No study participants 
were found positives for P. malariae or P. ovale infections. 
Thirty-nine patients had WHO-defined severe malaria [22] 
and two patients had non-severe malaria (Figure 1). Four 
patients were 15 years of age or below.Thirty patients had 
severe Pv infection, with a median age of 33.5 years (± 23.5), 
and a male to female ratio of 16:14 (Table 2). Eight patients 
had severePf infection, with a median age of 28.0 years (± 
26.0), and a male to female ratio of 5:3. Only one patient had 
severe Pf/Pv co-infection (Figure 1). The odds of being 
admitted to the hospital with a diagnosis of Pv relative to 
Pf were OR = 0.94; 95%CI (0.45–1.95); p = 0.864. Pv 
patients had significantly higher sexual and asexual para-
sitemia compared to Pf, and Pf patients had wider varia-
tions in white blood cell counts (Suppl. Figure 1). 
Thrombocytopenia, a common complication of Pf and Pv 
malaria [29], was observed in both groups (Suppl. Figure 1); 
84.6% and 41% of all severe malaria patients used public 
tanks or pumps as the water source and were below the 
poverty line, respectively; 43.6% and 25.6% of them lived in 
the thatch houses and worked as daily labours for their 
survival, respectively. The majority of the study participants 
(78%) were from Ahmedabad city, 17.1% of the patients 
were from Vadodara, Radhanpur, Surendranagar, 
Gandhinagar, Kheda, and Mehsana districts, and two 
(4.9%) patients were from Rajasthan. There was no signifi-
cant difference between Pv and Pf infection when these 
demographic, socioeconomic, and epidemiological charac-
teristics were compared. Ten severe malaria patients 
required blood transfusion, 7 out of 10 were infected with 
Pv parasites. Severe malaria Pf patients required assisted 
breathing (n = 3), dialysis (n = 1) and nasogastric tube 
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(n = 2). The patient with both Pf/Pv co-infection presented 
complaints such as headache, chills, pains, vomiting, dizzi-
ness, elevated heart rate (96 beats/minutes) as well as 
increased bilirubin (24.5 mg/dL), urea (102 mg/dL), and 
creatinine (4.87 mg/dL) levels. Blood cultures were negative 
for all but one patient, who tested positive for Bacillus 
Figure 1. Flowchart of the study: of the initial 50 patients enrolled in the study, 9 were negative using PCR. Two did not match the 
WHO criteria for severe malaria, and of the 39 severe malaria cases, 30 were infected with P. vivax (Pv), 8 with P. falciparum (Pf), and 
one with both parasite species.
Table 2. Demographic, socioeconomic, and epidemiological characteristics of severe malaria patients at 
the time of admission. Unless otherwise stated, values are expressed in the number of patients; percen-
tages are in brackets. P-values were obtained by Chi-square or Mann–Whitney U tests; NA: not applicable; 
IQR: interquartile range; Pv: P. vivax; Pf: P. falciparum.
Pv (n = 30) Pf (n = 8) p Value
Female 14 (46.7) 3 (37.5) 0.6431
Age, y, median±IQR 33.5 ± 23.5 28.0 ± 26.0 0.5319
Education status
Primary school 19 (63.3) 5 (62.5) 0.3412
Secondary school 6 (20.0) 3 (37.5)
None 5 (16.7) 0
Occupation
Daily labour 9 (30.0) 1 (12.5) 0.3004
Salary service 7 (23.3) 4 (50.0)
Other 14 (46.7) 3 (37.5)
Annual income
Above poverty line 20 (66.7) 3 (37.5) 0.1337
Below poverty line 10 (33.3) 5 (62.5)
House structure
Brick/concrete/other 16 (53.3) 5 (62.5) 0.6431
Thatch 14 (46.7) 3 (37.5)
Water source
Bore well 3 (10.0) 2 (25.0) 0.2648
Public tank/pump/other 27 (90.0) 6 (75.0)
Malaria history
Yes 5 (16.7) 1 (12.5) 0.774
No 25 (83.3) 7 (87.5)
Co-infections
Yes 6 (20.0) 0 0.1681
No 24 (80.0) 8 (100.0)
Pregnancy
Yes 2 (14.3) 0 0.4858
No 12 (85.7) 3 (100.0)
Weight, kg, median±IQR 60.0 ± 13.3 61.0 ± 17.0 0.9648
Height, cm, median±IQR 160.0 ± 11.8 164.0 ± 18.3 0.4641
Heart rate, beats/minutes, median±IQR 88.0 ± 15.0 84.0 ± 12.0 0.3601
Temperature °C, median±IQR 37.2 ± 0.4 37.2 ± 0.2 0.2798
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subtilis but was not categorized as having sepsis due to the 
individual’s clinical condition and immunocompetence. 
G6PD deficiency was only tested when deemed necessary 
by the physician, after asking the patient for any known 
blood disorders.6 Pv patients were tested for G6PD defi-
ciency, and only one individual was positive.
Severe and non-severe Plasmodium vivax malaria
Among 30 severe Pv cases, 16.7% (5/30) of the patients had 
history of fever or malaria in the previous 12 months and 
20% (6/30) of them also had typhoid (n = 1), dengue (n = 1), 
chikungunya (n = 1), or tuberculosis (n = 1) co-infections; 
23.3% (7/30) of patients came with fever (≥37.5°C). The 
median heart rate and body temperature were 88.0°C and 
37.2°C, respectively. The demographic, socioeconomic, and 
epidemiological characteristics of these patients are pre-
sented in Table 2. Patients presented a variety of symptoms 
such as chills (100%), headache (96.7%), vomiting (76.7%), 
and abdominal pain (73.3%) (Table 3). Among the hema-
tological parameters, platelet counts were recorded for only 
80% (24/30) of patients, thrombocytopenia (<150,000 pla-
telets/µL) was found in 58.3% of the patients (14/24), and 
29.2% of the patients (7/24) presented severe thrombocy-
topenia (<50,000 platelets/µL). The hematological and bio-
chemical parameters of these patients are presented in 
Table 4. Among severe Pv cases, prostration (n = 27) was 
the most prevalent of the severe malaria signs (Table 5), 
followed by multiple convulsions (n = 21), renal impair-
ment (n = 12), and clinical jaundice (n = 10). Information 
on symptoms of the severity of the remaining patients is 
presented in Table 5. Two non-severe malaria patients had 
a better socioeconomic status, no history of fever or malaria 
in the previous 12 months, no co-infections, and better 
hematological and biochemical parameters. No Pv infected 
patients presented primaquine-associated hemolysis and 
related complications.
Severe Plasmodium falciparum malaria
Out of 8 severe Pf cases, 12.5% (1/8) of the patients had 
a previous history of fever or malaria in the previous 12 
months and no co-infections were found. Only one 
patient had a complaint of fever (≥37.5°C). The median 
heart rate and body temperature were 84.0°C and 37.2°C, 
respectively. The demographic, socioeconomic, and epi-
demiological characteristics of these patients are pre-
sented in Table 2. Patients complained of headache 
(100%), chills (100%), vomiting (87.5%), and abdominal 
pain (75%). Among the hematological parameters, plate-
let counts were recorded for only 87.5% (7/8) of patients, 
thrombocytopenia (<150,000 platelets/µL) was found in 
42.9% of the patients (3/7), and 57.1% of the patients (4/7) 
presented severe thrombocytopenia (<50,000 platelets/ 
µL). The hematological and biochemical parameters of 
these patients are presented in Table 4. Among severe 
Table 3. Summary of clinical signs and symptoms of enrolled 
severe malaria patients. Values are expressed in the number of 
patients and percentages are in brackets. P-values were 
obtained by Chi-square test; NA: not applicable; Pv: P. vivax; 
Pf: P. falciparum.
Pv Pf p Value
Headache 29 (96.7) 8 (100.0) 0.6007
Chills 30 (100.0) 8 (100.0) NA
Aches or pains 16 (53.3) 3 (37.5) 0.4261
Fatigue 5 (16.7) 3 (37.5) 0.1991
Vomiting 23 (76.7) 7 (87.5) 0.5043
Lack of appetite 9 (30.0) 2 (25.0) 0.7817
Cough 9 (30.0) 4 (50.0) 0.2894
Dizziness 5 (16.7) 1 (12.5) 0.774
Sweating 1 (3.3) 2 (25.0) 0.0435
Abdominal pain 22 (73.3) 6 (75.0) 0.9242
Diarrhoea 3 (10.0) 1 (12.5) 0.8378
Lower back pain 4 (13.3) 1 (12.5) 0.9506
Eye pain 0 (0) 0 (0) NA
Paleness 0 (0) 0 (0) NA
Chest pain 2 (6.7) 0 (0) 0.4531
Rash 0 (0) 0 (0) NA
Ear pain 0 (0) 0 (0) NA
Splenomegaly 0 (0) 0 (0) NA
Table 4. Hematological and biochemical laboratory findings of 
severe malaria patients. Values are expressed in median ± 
interquartile range; patient numbers are in brackets. P-values 
were obtained by Mann–Whitney U tests; NA: not applicable; 
Pv: P. vivax; Pf: P. falciparum.
Pv Pf p Value
Hemoglobin levels (g/dL) 10.7 ± 3.8 (27) 8.1 ± 5.6 (8) 0.0568
Hematocrit (%) 33.9 ± 12.7 (27) 24.5 ± 19.5 (8) 0.0147
Platelet counts (x109/L) 67.0 ± 72.8 (24) 42.0 ± 72.0 (7) 0.1492
Serum bilirubin (mg/dL) 2.7 ± 2.9 (22) 2.0 ± 1.7 (3) 0.3483
Serum creatinine (mg/dL) 0.8 ± 0.4 (22) 0.9 ± 9.4 (3) 0.1304
Blood urea (mg/dL) 25.2 ± 18.5 (22) 51.2 ± 87.9 (3) 0.107
ALT levels (U/L) 24.1 ± 64.6 (21) 72.0 ± 67.8 (3) 0.6196
Blood glucose (mg/dL) 127.0 ± 42.5 (5) 126.0 ± 74.8 (5) 0.9444
Sodium levels (mmol/L) 134.5 ± 10.7 (16) 130.3 ± 6.5 (2) 0.268
Table 5. Summary of symptoms of the severity of patients 
enrolled in the study according to WHO criteria of severe 
malaria. Values are expressed in the number of patients and 
percentages are in brackets. P-values were obtained by the chi- 
square test; NA: not applicable; Pv: P. vivax; Pf: P. falciparum.
Symptoms Pv Pf p Value
Impaired consciousness 0 (0) 1 (12.5) 0.0497
Prostration 27 (90) 8 (100) 0.3514
Multiple convulsions 21 (70) 7 (87.5) 0.3179
Deep breath and respiratory distress 0 (0) 2 (25) 0.0049
Acute respiratory distress syndrome 0 (0) 0 (0) NA
Shock 1 (3.3) 0 (0) 0.6007
Clinical jaundice 10 (33.3) 0 (0) 0.0571
Abnormal bleeding 1 (3.3) 0 (0) 0.6007
Hypoglycemia 0 (0) 0 (0) NA
Metabolic acidosis 1 (3.3) 0 (0) 0.6007
Severe anemia 1 (3.3) 2 (25) 0.0435
Hemoglobinurea 1 (3.3) 0 (0) 0.6007
Hyperlactatemia 0 (0) 0 (0) NA
Renal impairment 12 (40) 3 (37.5) 0.8977
Pulmonary edema 0 (0) 0 (0) NA
Hyperparasitemia 0 (0) 0 (0) NA
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Pfpatients, prostration (n = 8) was the most prevalent of 
the severe malaria signs (Table 5), followed by multiple 
convulsions (n = 7) and renal impairment (n = 3). Two 
(25%) patients had severe anemia and 2 (25%) had deep 
breathing and respiratory distress. Details of severity 
symptoms for the remaining patients are presented in 
Table 5. Significant differences were observed for sweat-
ing (p = 0.043), hematocrit (p = 0.015), impaired con-
sciousness (p = 0.049), deep breathing and respiratory 
distress (p < 0.01), and severe anemia (p = 0.043) when 
compared between severe Pfand Pvgroups. However, 
clinically, these differences do not appear to be significant 
due to the small sample size. In addition, it is noteworthy 
that for the same reason, these differences are not signifi-
cant once a correction for multiple testing is applied.
Follow-up and severe malaria-associated deaths
All study participants (30 with severe Pv, 8 with severe 
Pf, 2 with non-severe Pv, and 1 with Pf/Pv co-infection) 
were admitted in hospital wards and were followed, 
treated, and evaluated until discharge, lasting for 
3.39 days (± 2.13) in the hospital. No significant differ-
ence (p = 0.538) was observed for hospital admission 
duration between severe Pf (3.40 days ± 1.85) and Pv 
(3.86 days ± 3.14) patients; 78% (32/41) patients recov-
ered, 14.6% (6/41) patients were discharged against the 
physician’s advice and 7.3% (3/41) patients died. Two 
of the fatal cases had Pf mono-infections and 1 Pf/Pv 
co-infection.
Discussion
The benign nature of Pv infections has been widely 
challenged over the recent years, and studies using 
stringent diagnosis techniques demonstrated a similar 
risk of severe disease and death as with Pf [30].A 
comprehensive clinical characterization of acute Pv 
infection relying on molecular tools is pivotal to better 
understand the pathogenetic mechanisms leading to 
severe disease and inform not only clinical manage-
ment but also new adjunct therapies. In endemic 
areas with low parasite densities and transmission 
where Pv is becoming the dominant species [31], the 
use of PCR-based assays is highly recommended as 
microscopy is not sensitive enough for routine malaria 
screening [9,11,32,33]. We therefore focused solely on 
PCR-positive patients in this study, as precise data on 
Pv burden is crucial to designing and implementing 
effective malaria control and elimination policies in 
India, where the Government has set an elimination 
target for 2030 [34].
We identified a higher frequency of severe Pv cases 
compared to Pf, which is consistent with the higher 
prevalence of the former species in the region [12]. 
The majority of study participants had a lower socio-
economic status and were from Ahmedabad; 29.2% of 
severe malaria patients presented severe thrombocyto-
penia. Prostration, multiple convulsions, renal impair-
ment, clinical jaundice, severe anemia, and deep 
breathing and respiratory distress were prevalent 
among the symptoms of severity.
Jaundice was only observed in severe Pv cases, which 
aligns with data reported in previous studies, where it was 
the most common complication seen in severe vivax 
infections [9,35,36]. Hepatic injury causing jaundice and 
increased liver enzyme levels have also been associated 
with severe Pf infection [37–40]. However, elevated ala-
nine aminotransferase (n = 6) and bilirubin (n = 10) levels 
in our cohort indicate that hepatic dysfunction was also 
present in study participants with severe Pv infection, 
suggesting that a combination of both hepatic dysfunction 
and hemolysis may be at play. One severe Pv patient had 
hemoglobinuria, but hypoglycemia was not detected in 
any of the enrolled patients. Although infrequent, hypo-
glycemia has been reported in severe Pv patients [9,41,42]. 
Severe Pf patients from our cohort presented two or more 
symptoms of severity on admission, while four or more 
were only seen in severe Pv patients. However, this did 
not affect the length of stay at the hospital. A high fre-
quency of multiple convulsions was recorded in severe Pv 
cases. Because the occurrence of convulsions is not 
a WHO-defined criterion of severity for Pv infection, 
the history of epilepsy was not documented as part of 
our clinical protocol. A possible explanation is that these 
patients had a previous history of epilepsy, and convul-
sions were triggered by fever during Pv infection. Three 
patients enrolled in this study died. Two had Pf mono- 
infections and one Pf/Pv co-infection, indicating a higher 
fatality rate inPfcompared to Pvpatients. This is in line 
with malaria-associated mortality data from the same 
hospital, which recorded a case fatality rate of 10.1% in 
Pf(43/425) compared to 5% in Pv(16/323) in 2011.
SeverePv cases are treated with a 3-day course of chlor-
oquine (25 mg/kg) followed by a 14-day course of prima-
quine (0.25 mg/kg). The use of primaquine prevents 
relapse by killing the dormant liver stages of Pv. 
However, the drug presents greater risks of hemolysis in 
G6PD-deficient patients [12,43,43]. G6PD deficiency is an 
X-linked inheritance, affecting 400 million people world-
wide [43]. The overall magnitude of G6PD deficiency 
prevalence in India is considered to be high [44–46], 
with an estimated prevalence of G6PD deficiency ranging 
from 4.2% to 10.8% in Gujarat [12,47]. Following clinical 
assessments, six Pvpatients enrolled in this study 
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underwent G6PD deficiency testing, and only one indivi-
dual was found positive. In accordance with the Indian 
national policy, all G6PD-negative,Pv-infected patients 
were treated with primaquine [23], and no side effects 
were observed in our cohort. While this may indicate 
that the use of primaquine in the local population could 
be safer than initially evaluated, systematic G6PD defi-
ciency testing will be necessary to successfully implement 
radical cure regimens for Pv and support future malaria 
elimination efforts [48].
Socioeconomic factors have been shown to influence 
malaria case management, as they promote causal 
behaviors and choices [49,50]. In the present study, 
41% (16/39) of participants were below the poverty 
line, 64.1% (25/39) only gained primary school educa-
tion, 43.6% (17/39) were living in thatched houses, and 
84.6% (33/39) of participants used public tanks/pumps 
as the water source. This indicates that the socioeco-
nomic status of the majority of participants was low, 
which might have affected or delayed the decision on 
when and where to seek malaria treatment. Early and 
prompt treatment of severe malaria is critical in 
improving the prognosis, as any delay could lead to life- 
threatening outcomes. Previous studies have also asso-
ciated lack of education, low income, and living in 
poorly constructed houses with increased risk of 
Plasmodium infection [51,52]. Therefore, efforts to con-
trol and eliminate malaria should also include invest-
ment in the socioeconomic development of malaria- 
endemic areas, which may have a substantial impact 
against malaria in the long term [51].
India has the world’s largest national malaria control 
program [34,53], which has led to a significant reduction 
in malaria transmission over the last decade [6]. In 
a study recently conducted by our group, almost all 
infections in both clinic and community surveys at 
another site in Gujarat were detectable by microscopy. 
Because the area has a history of low malaria prevalence, 
residents can be expected to have low immunity, which 
may explain why most infections will develop parasite-
mia not only detectable by microscopy but also will lead 
to clinical episodes [26]. The proportion ofPv-positive 
cases in this other site was 85.9% (61/71) and 83.3% 
(55/66) by microscopy and PCR, respectively [26], 
which aligns with 78% (32/41) of Pv cases reported in 
the present study. Collectively, these findings suggest that 
the recent decline in malaria transmission in India has 
not affected the overall ratio of Pv: Pf in Gujarat, which 
was reported to be 80:20 in 2014 [12]. However, the 
decrease of the development of naturally acquired immu-
nity against the infection resulting from a reduction of 
transmission may lead to less total cases, but potentially 
an increase in severe cases [54]. Only one patient with 
severe Pv was under 15 years in our cohort, a proportion 
of 3.3% that is ten-fold lower than the 30% of the patients 
under 14 with severe Pv reported across India in 2016 
[12]. Incidentally, the number of Pv cases in Gujarat has 
declined steadily since 2004, and the lack of exposure 
may explain this shift in the age of the patients with 
severe disease [12]. Our findings further support the 
need for epidemiological studies combining clinical char-
acterization of severe Pv malaria and serological evalua-
tion of exposure markers to monitor the impact of 
elimination programmes in the future.
In conclusion, severe malaria due to Pv was more 
frequent than severe Pf infection among patients admitted 
at Ahmedabad Civil Hospital, and it affected predomi-
nantly adults. Their clinical presentation was in line with 
previous reports, and the overall fatality rate due to severe 
malaria was lower than average (~7%). The present report 
contributes to our understanding of the disease spectrum 
of severe Pvmalaria in India and is indicative of a high 
prevalence of severe Pv in Ahmedabad, which should be 
considered in local malaria elimination campaigns.
Acknowledgments
We thank the staff of the Ahmedabad Civil hospital, as well as Drs 
Lalitha Ramanathapuram and Annie Kessler for their logistical 
support. We also thank Dr.NeenaValecha, the former Director of 
ICMR-NIMR for facilitating the study, and the staff of the NIMR 
Field Unit Nadiad for their participation. The research reported 
in this publication was supported by the National Institute of 
Allergy and Infectious Diseases of the National Institutes of 
Health under Award Number U19AI089676 as part of the 
International Centers for Excellence in Malaria Research. SCW 
is supported by a grant from the UK Medical Research Council, 
award number MR/S009450/1. The content is solely the respon-
sibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health.
Disclosure statement
The authors have no conflict of interest to declare.
Funding
This work was supported by the National Institute of Allergy 
and Infectious Diseases [U19AI089676].
ORCID
Samuel C. Wassmer http://orcid.org/0000-0002-6753-3376
736 A. R. ANVIKAR ET AL.
References
[1] Howes RE, Battle KE, Mendis KN, et al. Global epide-
miology of Plasmodium vivax. Am J Trop Med Hyg. 
2016;95:15–34.
[2] Mackintosh CL, Beeson JG, Marsh K. Clinical features 
and pathogenesis of severe malaria. Trends Parasitol. 
2004;20:597–603.
[3] Mueller I, Galinski MR, Baird JK, et al. Key gaps in the 
knowledge of Plasmodium vivax, a neglected human 
malaria parasite. Lancet Infect Dis. 2009;9:555–566.
[4] Carlton JM, Sina BJ, Adams JH. Why is Plasmodium 
vivax a neglected tropical disease? PLoS Negl Trop Dis. 
2011;5:e1160.
[5] Joshi H, Prajapati SK, Verma A, et al. Plasmodium 
vivax in India. Trends Parasitol. 2008;24:228–235.
[6] WHO World Health Organization. World Malaria 
Report. 2018.
[7] Gupta H, Afsal MP, Shetty SM, et al. Plasmodium vivax 
infection causes acute respiratory distress syndrome: 
a case report. J Infect Dev Ctries. 2015;9:910–913.
[8] Gupta H, Dhunputh P, Bhatt AN, et al. Cerebral malaria 
in a man with Plasmodium vivax mono-infection: a case 
report. Trop Doct. 2016;46:241–245.
[9] Kochar DK, Das A, Kochar SK, et al. Severe 
Plasmodium vivax malaria: a report on serial cases 
from Bikaner in northwestern India. Am J Trop Med 
Hyg. 2009;80:194–198.
[10] Rahimi BA, Thakkinstian A, White NJ, et al. Severe 
vivax malaria: a systematic review and meta-analysis of 
clinical studies since 1900. Malar J. 2014;13:481.
[11] Siqueira AM, Lacerda MV, Magalhaes BM, et al. 
Characterization of Plasmodium vivax-associated 
admissions to reference hospitals in Brazil and India. 
BMC Med. 2015;13:57.
[12] Anvikar AR, Shah N, Dhariwal AC, et al. Epidemiology 
of Plasmodium vivax Malaria in India. Am J Trop Med 
Hyg. 2016;95:108–120.
[13] Joshi U, Solanki A, Oza U, et al. Situation of P. vivax 
malaria in Ahmedabad city: A study in purview of national 
guidelines. Ann Trop Med Public Health. 2013;6:227–231.
[14] Mayor A, Alano P. Bone marrow reticulocytes: 
a Plasmodium vivax affair? Blood. 2015;125:1203–1205.
[15] Miller LH, Mason SJ, Clyde DF, et al. The resistance factor 
to Plasmodium vivax in blacks. The Duffy-blood-group 
genotype, FyFy. N Engl J Med. 1976;295:302–304.
[16] Anstey NM, Handojo T, Pain MC, et al. Lung injury in 
vivax malaria: pathophysiological evidence for pulmonary 
vascular sequestration and posttreatment alveolar-capillary 
inflammation. J Infect Dis. 2007;195:589–596.
[17] Baro B, Deroost K, Raiol T, et al. Plasmodium vivax 
gametocytes in the bone marrow of an acute malaria 
patient and changes in the erythroid miRNA profile. 
PLoS Negl Trop Dis. 2017;11:e0005365.
[18] Lacerda MV, Fragoso SC, Alecrim MG, et al. 
Postmortem characterization of patients with clinical 
diagnosis of Plasmodium vivax malaria: to what extent 
does this parasite kill? Clin Infect Dis. 2012;55:e67–74.
[19] Machado Siqueira A, Lopes Magalhaes BM, Cardoso 
Melo G, et al. Spleen rupture in a case of untreated 
Plasmodium vivax infection. PLoS Negl Trop Dis. 2012;6: 
e1934.
[20] Obaldia N 3rd, Meibalan E, Sa JM, et al. Bone marrow 
is a major parasite reservoir in plasmodium vivax 
infection. mBio. 2018;9:e00625-18.
[21] Organization WH. Guidelines for the treatment of 
malaria. 3rd ed. 2015.
[22] WHO. Severe malaria. Trop Med Int Health. 
2014;19:7–131.
[23] Research NIoM. Guidelines for the diagnosis and treat-
ment of malaria in India. 2011.
[24] Rubio JM, Benito A, Berzosa PJ, et al. Usefulness of 
seminested multiplex PCR in surveillance of imported 
malaria in Spain. J Clin Microbiol. 1999;37:3260–3264.
[25] Rubio JM, Benito A, Roche J, et al. Semi-nested, multi-
plex polymerase chain reaction for detection of human 
malaria parasites and evidence of Plasmodium vivax 
infection in Equatorial Guinea. Am J Trop Med Hyg. 
1999;60:183–187.
[26] van Eijk AM, Sutton PL, Ramanathapuram L, et al. The 
burden of submicroscopic and asymptomatic malaria 
in India revealed from epidemiology studies at three 
varied transmission sites in India. Sci Rep. 
2019;9:17095.
[27] Harris PA, Taylor R, Thielke R, et al. Research electro-
nic data capture (REDCap)–a metadata-driven metho-
dology and workflow process for providing 
translational research informatics support. J Biomed 
Inform. 2009;42:377–381.
[28] Ruhamyankaka E, Brunk BP, Dorsey G, et al. 
ClinEpiDB: an open-access clinical epidemiology data-
base resource encouraging online exploration of com-
plex studies. Gates Open Res. 2019;3:1661.
[29] Lacerda MV, Mourao MP, Coelho HC, et al. 
Thrombocytopenia in malaria: who cares? Mem Inst 
Oswaldo Cruz. 2011;106(Suppl 1):52–63.
[30] Baird JK. Evidence and implications of mortality asso-
ciated with acute Plasmodium vivax malaria. Clin 
Microbiol Rev. 2013;26:36–57.
[31] Commons RJ, Simpson JA, Thriemer K, et al. Risk of 
Plasmodium vivax parasitaemia after Plasmodium fal-
ciparum infection: a systematic review and 
meta-analysis. Lancet Infect Dis. 2019;19:91–101.
[32] Gupta H, Srivastava S, Chaudhari S, et al. New mole-
cular detection methods of malaria parasites with mul-
tiple genes from genomes. Acta Trop. 2016;160:15–22.
[33] Siwal N, US S, Dash M, et al. Malaria diagnosis by PCR 
revealed differential distribution of mono and mixed 
species infections by Plasmodium falciparum and 
P. vivax in India. PLoS One. 2018;13:e0193046.
[34] Ghosh SK, Rahi M. Malaria elimination in India-The 
way forward. J Vector Borne Dis. 2019;56:32–40.
[35] Mohapatra MK, Padhiary KN, Mishra DP, et al. 
Atypical manifestations of Plasmodium vivax malaria. 
Indian J Malariol. 2002;39:18–25.
[36] Naik BS. Incidence of jaundice in Plasmodium vivax 
malaria: A prospective study in Moodabidri, South 
India. Malays J Med Sci. 2014;21:24–27.
[37] Anand AC, Ramji C, Narula AS, et al. Malarial hepatitis: 
a heterogeneous syndrome? Natl Med J India. 
1992;5:59–62.
[38] Chawla LS, Sidhu G, Sabharwal BD, et al. Jaundice in 
Plasmodium falciparum. J Assoc Physicians India. 
1989;37:390–391.
VIRULENCE 737
[39] Kochar DK, Agarwal P, Kochar SK, et al. Hepatocyte 
dysfunction and hepatic encephalopathy in 
Plasmodium falciparum malaria. QJM. 
2003;96:505–512.
[40] Kochar DK, Singh P, Agarwal P, et al. Malarial 
hepatitis. J Assoc Physicians India. 
2003;51:1069–1072.
[41] Abdallah TM, Abdeen MT, Ahmed IS, et al. Severe 
Plasmodium falciparum and Plasmodium vivax 
malaria among adults at Kassala Hospital, eastern 
Sudan. Malar J. 2013;12:148.
[42] Zubairi AB, Nizami S, Raza A, et al. Severe 
Plasmodium vivax malaria in Pakistan. Emerg Infect 
Dis. 2013;19:1851–1854.
[43] Baird JK. Reinventing primaquine for endemic malaria. 
Expert Opin Emerg Drugs. 2012;17:439–444.
[44] Kumar P, Yadav U, Rai V. Prevalence of 
glucose-6-phosphate dehydrogenase deficiency in India: 
an updated meta-analysis. Egyptian J Med Human Gene. 
2016;17:295–302.
[45] Mohanty D, Mukherjee MB, Colah RB. Glucose- 
6-phosphate dehydrogenase deficiency in India. 
Indian J Pediatr. 2004;71:525–529.
[46] Mukherjee MB, Colah RB, Martin S, et al. Glucose- 
6-phosphate dehydrogenase (G6PD) deficiency among 
tribal populations of India - Country scenario. Indian 
J Med Res. 2015;141:516–520.
[47] Mohanty D, Sukumar S, Mukherjee MB, et al. G6PD defi-
ciency and malaria in India. Am J Hematol. 
2003;72:150–151.
[48] Recht J, Ashley EA, White NJ. Use of primaquine and 
glucose-6-phosphate dehydrogenase deficiency testing: 
divergent policies and practices in malaria endemic 
countries. PLoS Negl Trop Dis. 2018;12:e0006230.
[49] Anyanwu PE, Fulton J, Evans E, et al. Exploring the 
role of socioeconomic factors in the development and 
spread of anti-malarial drug resistance: a qualitative 
study. Malar J. 2017;16:203.
[50] Berkman LF, Kawachi I, Glymour MM. Social epide-
miology. Oxford, UK: Oxford University Press; 2014. 
https://oxfordmedicine.com/view/10.1093/med/ 
9780195377903.001.0001/med-9780195377903
[51] Degarege A, Fennie K, Degarege D, et al. Improving 
socioeconomic status may reduce the burden of 
malaria in sub Saharan Africa: A systematic review 
and meta-analysis. PLoS One. 2019;14:e0211205.
[52] Tusting LS, Ippolito MM, Willey BA, et al. The evidence for 
improving housing to reduce malaria: a systematic review 
and meta-analysis. Malar J. 2015;14:209.
[53] WHO World Health Organization. World Malaria Report. 
2014.
[54] Fowkes FJ, Boeuf P, Beeson JG. Immunity to malaria in 
an era of declining malaria transmission. Parasitology. 
2016;143:139–153.
738 A. R. ANVIKAR ET AL.
